基于处方的P-葡萄糖蛋白基质与阿尔茨海默病风险的相关性:一项嵌套病例对照研究
Joseph Asante1, Corey L Nagel2,3, Steven W Barger4,5,6
1Graduate Program in Bioinformatics, University of Arkansas at Little Rock, Little Rock, AR, USA.
Journal of Alzheimer's disease : JAD
|June 24, 2025
概括
使用与P-glycoprotein (P-gp) 相互作用的处方药可能会降低阿尔茨海默病 (AD) 的风险. 需要进一步的研究来证实特定的P-gp基质对AD发展的影响.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- P-glycoprotein (P-gp) 在从中枢神经系统 (CNS) 中清除粉样β (Aβ) 中起作用.
- 其他P-gp基质 (Pgp-S) 可能会影响Aβ清除,可能通过竞争性或合作性运输机制影响阿尔茨海默病 (AD) 风险.
研究的目的:
- 调查使用Pgp-S药物与患AD的风险之间的关联.
- 为了确定Pgp-S药物是否通过改变Aβ清除途径影响AD风险.
主要方法:
- 一项使用 PharMetrics Plus 数据库 (IQVIA) 的回顾性队列研究.
- 参与者包括70,340名处方Pgp-S药物的使用者和352,382名非使用者,根据年龄,性别和地理区域进行匹配.
- 考克斯回归模型被用于调整共变量和并发症.
主要成果:
- 使用Pgp-S与AD危险比率显著降低相关 (HR=0.87;95%CI=0.78-0.98).
- 在患有并发症的患者中观察到较高的AD风险:抑郁症 (HR=4.44),中风 (HR=1.98),高血压 (HR=1.24).
- 迪戈辛,阿托瓦斯塔丁,奥梅普拉和普雷迪尼松等特定药物显示,阿尔茨海默病的几率下降,而里瓦罗克萨班和米拉贝格朗则趋向于增加风险.
结论:
- 这项研究表明,Pgp-S使用与阿尔茨海默病风险降低之间存在潜在的关联.
- 由于局限性,需要进一步调查,以确认单个PGPS药物对AD发展的具体影响和方向.
相关概念视频
01:26Alzheimer's Disease: Overview
684
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
684
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
01:11Genome-wide Association Studies-GWAS
14.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
14.4K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
184
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
184